Synairgen plc: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
( Synairgen or the Company )
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
Southampton, UK - 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with mild to moderate COVID-19 symptoms not yet requiring hospitalisation.
Richard Marsden, CEO of Synairgen, said:
About Synairgen Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta1a broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgen s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people
A new potentially life-saving inhaler-based treatment which is expected will defend COVID-19 patients from developing severe illness has commenced a major trial at hospitals in the United Kingdom. It involves inhaling a protein called interferon beta-1a (SNG001), which the body produces when it gets a viral infection, and the expectation is it will kindle the body’s immune system and prime cells to be ready to fight off viruses.
Notably, Synairgen’s SG018 trial is a randomized placebo-controlled study being conducted in approximately 20 countries enrolling a total of 610 COVID-19 patients who require supplemental oxygen. “We need treatments as well as vaccines to fight highly pathogenic viruses such as SARS-CoV-2 [COVID-19]. Development of treatments like ours will remain necessary in cases where vaccines are not effective, for those who do not get vaccinated, and in case the virus mutates to the point where vaccines become less effective,” said Richard Marsden, CEO of Syn
Synairgen plc: Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
( Synairgen or the Company )
Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
Southampton, UK - 13 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen s inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 patients.
As previously announced, Synairgen has appointed Parexel Biotech, a division of the leading global clinical research organisation, Parexel, to help conduct the Phase III trial and several UK sites have now been initiated, with further sites in the US and the EU expected to follow. The trial is deemed an Urgen
A new potentially life-saving inhaler-based treatment which is hoped will protect COVID-19 patients from developing severe illness has begun a major trial at UK hospitals.